Michael Makris Shares French Regulatory Update: Marstacimab (Hympavzi) Not Recommended for Severe Haemophilia A or B
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared a post on Linkedin:
“Interesting development from France. The French authorities assessed marstacimab (Hympavzi) and concluded that it has no place in the therapeutic strategy for severe haemophilia A or B without inhibitors.
They questioned the robustness of the comparative assessment against other approved therapies and pointed to uncertainties in terms of safety.
The document is in French but Google translate does a pretty good job if you do not speak French. I attach the Google translate version of the conclusion. ”
Check out here for more.
Find more posts on Hemostasis Today.
-
Jun 2, 2026, 15:28Kabilan K. L.: Management and Diagnosis of Acute Coronary Syndrome Types
-
Jun 2, 2026, 15:26Mital Jhaveri: What New Data Reveal About DOACs and Androgen Receptor Inhibitors?
-
Jun 2, 2026, 15:22Dhananjaya Kotebagilu Narayana Vamyanmane: High-Resolution Ultrasound Evaluation of Bowel Wall Ischemia
-
Jun 2, 2026, 15:20Joep Schellens: Influence of Dexamethasone and Tocilizumab on Fibrinolysis in COVID-19
-
Jun 2, 2026, 15:12Ebrahim Umer: The Sickest Liver Patients Deserve One Language – Lessons from the Kyoto Consensus
-
Jun 2, 2026, 15:10Ney Carter Borges: Bempedoic Acid and Venous Thromboembolism Risk in Statin-Intolerant Patients
-
Jun 2, 2026, 15:07Sayan Koley: Coagulation Science – Where Precision Saves Lives
-
Jun 2, 2026, 15:04Ahmed Mohsen: Low CHA₂DS₂-VA Score Does Not Always Mean No Anticoagulation
-
Jun 2, 2026, 15:04The Risk Factors and Optimal Prevention Strategies of VTE in Sickle Cell Disease – RPTH Journal